Clinical Trial Update: 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating 24- versus 48-week pegylated interferon alfa-2a therapy for genotype 2/3 chronic hepatitis C was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Federico II University | Conditions: Chronic Hepatitis C | Phase 3 | Status: WITHDRAWN